Top-line results from the Phase III CheckMate-214 trial in metastatic renal cell carcinoma have been released by New York’s Bristol-Myers Squibb (NYSE: BMY).
The study compares a combination therapy of Opdivo (nivolumab) plus Yervoy (ipilimumab), Bristol-Myers’ immuno-oncological drugs, with the RTK inhibitor sunitinib.
First approved in 2006, sunitinib is marketed by Pfizer (NYSE: PFE) as Sutent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze